Same Drug Class

Levofloxacin vs Moxifloxacin

Overview

Both levofloxacin and moxifloxacin are respiratory fluoroquinolones used for CAP and other respiratory tract infections. Moxifloxacin adds anaerobic activity but cannot be used for UTI. Levofloxacin maintains urinary efficacy.

Mechanism of Action

Both inhibit DNA gyrase and topoisomerase IV. Moxifloxacin's C8-methoxy group provides greater anaerobic activity. Both are concentration-dependent antibiotics.

Antimicrobial Spectrum

Levofloxacin: excellent S. pneumoniae, moderate Pseudomonas, excellent atypicals, no anaerobes. Moxifloxacin: similar to levofloxacin plus excellent anaerobic coverage, better S. aureus, no Pseudomonas.

Clinical Comparison

For CAP: both guideline-recommended as monotherapy (IDSA/ATS). For complicated intra-abdominal infections: moxifloxacin can be used as monotherapy (anaerobic coverage); levofloxacin requires addition of metronidazole. For UTI: levofloxacin only.

QTc

Both prolong QTc; moxifloxacin more than levofloxacin.

Key Takeaways

  • Both respiratory FQs for CAP; moxifloxacin adds anaerobic coverage
  • Levofloxacin: can treat UTI; moxifloxacin cannot
  • Moxifloxacin: greater QTc risk

Fazit

For CAP, both are equivalent first-line options. Moxifloxacin is preferred when anaerobic coverage is needed without a second agent. Levofloxacin is preferred when UTI or Pseudomonas coverage is required. QTc risk is higher with moxifloxacin.